A new study from the Centers for Disease Control and Prevention (CDC) is raising alarms about the hidden prevalence of alpha-gal syndrome, a potentially life-threatening meat allergy triggered by tick bites. According to a report published in the agency's 'Morbidity and Mortality Weekly Report' on July 2, 2026, an estimated 24% of adults in five high-risk states carry antibodies linked to the condition—far more than previously recognized.
The findings were highlighted in a recent article by 'The Focal Points', a Substack publication authored by Dr. Peter McCullough, which noted that the new data suggest alpha-gal sensitization is far more widespread than earlier estimates indicated.
The CDC study tested 3,000 residual blood donor samples collected between November 2024 and April 2025 from residents of 10 states. Researchers found that the five states with the highest seroprevalence—Arkansas, Kentucky, Missouri, Tennessee, and Virginia—showed an alpha-gal immunoglobulin E (IgE) antibody rate of 24.0%. The analysis included five additional states with historically lower disease activity to provide regional comparison.
Alpha-gal syndrome (AGS) is an acquired allergy to mammalian meat products, including pork, beef, and lamb, as well as dairy and certain by-products. Most cases are linked to bites from the lone star tick (*Amblyomma americanum*), whose saliva contains the alpha-gal sugar molecule. When transferred to humans through a bite, it can trigger the immune system to produce alpha-gal-specific IgE antibodies, leading to delayed allergic reactions that can range from hives and gastrointestinal distress to severe anaphylaxis.
The CDC's prior research estimated that as many as 450,000 Americans were affected by AGS as of 2022, but those figures were based on reported clinical diagnoses. The new blood donor study captures asymptomatic individuals as well—people who carry the antibodies but have not yet experienced or recognized allergic symptoms. This distinction is critical, researchers say, because it suggests the true pool of sensitized individuals is substantially larger than the number of documented cases.
Public health experts caution that not everyone with detectable alpha-gal antibodies will develop clinical AGS. Sensitivity varies, and some individuals may carry the marker without ever reacting to mammalian products. However, the high seroprevalence in tick-heavy regions underscores the growing public health footprint of vector-borne diseases in the United States.
The study, led by first author Dr. Eleanor Saunders in collaboration with alpha-gal researcher Dr. Scott Commins of the University of North Carolina, represents one of the most comprehensive seroprevalence assessments to date. The use of blood donor samples allowed researchers to screen a broad cross-section of adults across geographically diverse areas.
For clinicians and public health officials, the findings signal a need for heightened awareness. Symptoms of AGS often appear hours after eating meat, making diagnosis difficult and frequently leading to under-recognition. Patients in high-prevalence regions who present with unexplained allergic reactions or gastrointestinal complaints may warrant alpha-gal testing, particularly if they have a history of tick exposure.
The CDC's findings also add to mounting evidence that climate change and expanding tick habitats are reshaping the landscape of allergic and infectious disease in America. As lone star tick populations continue to spread, the number of sensitized individuals—and ultimately those living with full-blown alpha-gal syndrome—may grow well beyond current projections.
